status 2 / 5 · 2 contributors

prediction metrics boltz-2 1.0

ipTM0.842

pTM0.552

avg pLDDT91.6

ranking score0.901

Hypotheses5 directions▾ collapse

Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.

openupdated 2026-06-05

Could replacing one weak spot in the peptide's structure make it last longer without breaking what makes it work?

If this holds, a small chemical swap could prevent the peptide from breaking down too fast in the gut or bloodstream, potentially making it useful as a lasting oral treatment for high blood pressure rather than just a food ingredient.

The hypothesis

Substituting the Met at position 2 of EMPFPK with norvaline or alpha-aminobutyric acid increases proteolytic stability and preserves ACE inhibitory potency, because the Met side chain is the primary site for oxidative and protease-mediated degradation without contributing to ACE active-site contacts.

Why it’s plausible

The axis-hit data on proteolytic stability (10.1248/cpb.c25-00478) indicates that residue-level substitutions can substantially improve serum half-life without ablating activity. Met is susceptible to oxidation and is a preferred cleavage site for certain endoproteases. In EMPFPK, the key ACE-binding pharmacophoric elements are the C-terminal Lys, the Pro residues at positions 3 and 5, and the Phe at position 4. Position-2 Met is therefore a substitution-tolerant site. Norvaline and alpha-aminobutyric acid are isosteres with similar chain length but no sulfur, providing proteolytic resistance while maintaining backbone geometry.

Why it matters

Improving half-life at a non-pharmacophoric position is a low-risk engineering approach that could transition EMPFPK from a food-functional peptide toward a more durable oral antihypertensive therapeutic.

Plausibility.67

Novelty.48

Impact.67

Basis · grounding1 paper · 2 computed/notes

[1]

sourceLiterature cited in proteolytic stability axis confirms that residue-level substitutions (here D-amino acids; by extension, isosteres) improve serum stability and inhibit protease recognition

[2]

paper

In-context note that bioactivity of low-molecular-weight peptides can be retained during gastrointestinal digestion, but explicit stability evaluation is still needed

doi: 10.1038/s41598-021-84820-7

[3]

sequenceEMPFPK: Met at position 2 is the only oxidizable or protease-susceptible residue outside the ACE pharmacophore (PFP core and C-terminal Lys); makes it a rational substitution target

openupdated 2026-06-05

Could the same peptide help control both blood pressure and blood sugar in people who have both conditions?

High blood pressure and type 2 diabetes frequently occur together, and current treatments address them separately. If EMPFPK inhibits both relevant enzymes, it could offer a single dietary compound with dual benefit for people dealing with metabolic syndrome.

The hypothesis

EMPFPK inhibits DPP-IV (dipeptidyl peptidase IV / CD26) in addition to ACE, due to its N-terminal Glu-Met dipeptide motif that is susceptible to DPP-IV cleavage and can competitively occupy the DPP-IV active site.

Why it’s plausible

DPP-IV preferentially cleaves after position 2 from peptide N-termini, with a preference for penultimate Pro or Ala. Although EMPFPK has Met at position 2 rather than Pro, several food-derived hexapeptides with non-canonical P2 residues have been shown to inhibit DPP-IV. The same milk casein hydrolysate literature that identified EMPFPK also systematically identified DPP-IV inhibitory activity in the same fractions (refs 10.1016/j.foodchem.2017.03.123, 10.1021/acs.jafc.5b03062), and the peptide's proline-rich core (positions 3 and 5) could anchor interactions at secondary binding subsites of DPP-IV.

Why it matters

If EMPFPK is a dual ACE/DPP-IV inhibitor, it would have combined antihypertensive and antidiabetic potential in a single hexapeptide scaffold, relevant to the metabolic syndrome phenotype where both hypertension and type-2 diabetes co-occur.

Plausibility.52

Novelty.47

Impact.75

Basis · grounding2 papers · 1 computed/note

[1]

paper

DPP-IV inhibitory peptides co-identified in bovine and goat milk casein hydrolysates from the same enzymatic fractionation pipelines used to identify EMPFPK

doi: 10.1016/j.foodchem.2017.03.123

[2]

paper

Goat milk casein hydrolysates were fractionated for DPP-IV inhibition and yielded peptides in the same molecular weight range as EMPFPK

doi: 10.1021/acs.jafc.5b03062

[3]

sequenceEMPFPK has N-terminal Glu-Met compatible with DPP-IV binding pocket geometry and proline residues at positions 3 and 5 that could anchor DPP-IV subsite contacts

openupdated 2026-06-05

Does the peptide need to curl into a particular shape to actually work?

If the peptide's activity depends on a specific curved shape created by two proline building blocks, researchers could use that knowledge to design stronger, more targeted analogs, and quickly screen out versions that would fail.

The hypothesis

The PFP triplet at positions 3-5 of EMPFPK constrains the peptide backbone into a type-II or type-VI beta-turn that presents the flanking Glu (position 1) and Lys (position 6) side chains on the same face, and this turn geometry is necessary for ACE binding affinity.

Why it’s plausible

Sequential Pro residues separated by one residue (Pro-X-Pro) frequently enforce beta-turn or polyproline II helix character in short peptides. In EMPFPK the triplet is P3-F4-P5, where P3 and P5 bracket a single Phe. This is structurally distinct from the classical Pro-Pro dipeptide but can still nucleate a turn, positioning the charged termini and the Glu1 carboxylate and Lys6 amine for bidentate ACE active-site contacts. The Boltz-2 complex prediction (avg_plddt 91.6, iptm 0.842) implies a well-folded bound conformation rather than a disordered extended chain.

Why it matters

If the PFP-induced turn is confirmed as the active conformation, truncation or linearization analogs (e.g., replacing either Pro with Ala) that disrupt the turn would lose activity, providing a direct structure-activity handle for analog design.

Plausibility.47

Novelty.55

Impact.63

Basis · grounding1 paper · 2 computed/notes

[1]

structureavg_plddt 91.6 and iptm 0.842 in Boltz-2 complex indicate the bound peptide adopts a confident folded pose, consistent with a constrained turn geometry

[2]

sequenceEMPFPK contains Pro at positions 3 and 5 flanking Phe4, a P-X-P motif known to enforce backbone rigidity and beta-turn-like geometries in hexapeptides

[3]

paper

Structure-function review of blood-pressure-lowering peptides stresses that amino acid composition and sequence constrain conformation and antihypertensive activity, with Pro content as a key determinant

doi: 10.1021/jf5002606

openupdated 2026-06-05

Could this peptide lower blood pressure without interfering with a blood cell process that some similar drugs disrupt?

ACE has two active zones, and hitting only one of them is thought to reduce unwanted side effects on blood cell regulation. If EMPFPK is selective in this way, it could be a cleaner option compared to other food-derived blood pressure peptides.

The hypothesis

EMPFPK selectively inhibits the C-domain active site of ACE over the N-domain active site, due to its proline-rich central motif (PFP) that matches the substrate preference profile of the ACE C-domain.

Why it’s plausible

ACE contains two homologous active sites (N-domain and C-domain) with distinct substrate preferences. The C-domain preferentially processes angiotensin I to angiotensin II and is therefore the primary antihypertensive target, while N-domain inhibition is linked to metabolism of AcSDKP (a hematopoietic peptide) and potential side effects. Short proline-containing peptides have shown C-domain preference in several studies. EMPFPK's PFP triplet at positions 3-5 is structurally analogous to the Pro-containing segments observed in C-domain-selective inhibitors, and domain-selectivity would favor a cleaner antihypertensive profile.

Why it matters

C-domain selective ACE inhibition avoids suppression of AcSDKP degradation, which may reduce hematopoietic side effects. This selectivity would be a meaningful differentiator relative to non-selective food-derived ACE inhibitors.

Plausibility.42

Novelty.58

Impact.72

Basis · grounding1 paper · 2 computed/notes

[1]

sequenceEMPFPK contains a PFP triplet (positions 3-5) that matches structural determinants of C-domain-selective ACE inhibitors described in the food peptide literature

[2]

paper

Buffalo milk casein-derived peptides were evaluated for ACE inhibition with domain selectivity as a differentiating feature among milk-protein peptides

doi: 10.1007/s00726-022-03202-z

[3]

structureBoltz-2 complex prediction with iptm 0.842 supports a defined binding pose consistent with single-site engagement rather than promiscuous multi-site binding

openupdated 2026-06-05

Does the peptide also neutralize harmful molecules that damage blood vessel walls, separate from its blood pressure effect?

Oxidative stress in blood vessels both causes and worsens high blood pressure. If EMPFPK can mop up damaging reactive molecules through one of its building blocks, it might protect the lining of blood vessels in ways that go beyond just lowering blood pressure readings.

The hypothesis

EMPFPK reduces oxidative stress in endothelial cells independently of its ACE inhibitory activity, because its Met residue at position 2 acts as a reactive oxygen species scavenger through reversible Met sulfoxidation.

Why it’s plausible

Methionine is uniquely susceptible to oxidation by reactive oxygen species (ROS), forming methionine sulfoxide in a reaction that quenches ROS. This antioxidant function is independent of ACE binding. In the context of hypertension, endothelial oxidative stress is both a driver and a consequence of elevated angiotensin II. A peptide that simultaneously inhibits ACE and scavenges ROS would address two complementary pathways. The milk peptide literature (10.1186/s43014-024-00280-2) notes antioxidant activity as a co-occurring property of milk-derived bioactive peptides, and the EMPFPK sequence has a Met residue accessible at position 2.

Why it matters

If EMPFPK has orthogonal antioxidant activity via Met oxidation, its cardioprotective potential extends beyond blood pressure normalization to endothelial protection and reduction of oxidative vascular damage.

Plausibility.53

Novelty.28

Impact.42

Basis · grounding2 papers · 1 computed/note

[1]

sequenceMet at position 2 of EMPFPK has a thioether side chain that undergoes reversible oxidation by ROS, a well-established peptide antioxidant mechanism

[2]

paper

Review of milk-derived bioactive peptides documents antioxidant activity as a parallel functional property of food-derived antihypertensive peptides

doi: 10.1186/s43014-024-00280-2

[3]

paper

Goat milk casein peptide fractions discussed in the context of MCF-7 breast cancer cell death and oxidative stress mechanisms, indicating antioxidant properties in casein-derived peptides beyond ACE inhibition

doi: 10.1007/s44463-026-00061-0

details expand to inspect

▸full evidence table2 metrics

metric	value	tool
ipTM	0.8424452543258667	boltz-2
ranking score	0.9010158777236938	boltz-2

▸structural qualityopenfold3

metric	value	note
gpde	1.083	global PDE — lower = better
disorder	NaN	fraction disordered

▸3-letter notation

Glu-Met-Pro-Phe-Pro-Lys

▸recipeboltz-2 1.0

parameter	value
model	boltz-2 1.0
weights	—
hardware	nvidia_nim_api
mlx version	—
python	—
random seed	—
msa strategy	none
diffusion samples	1
runtime	—
predicted by	mlx@peptide
predicted at	2026-04-24

▸citationbibtex

peptidemodel (2026). Blood-pressure-lowering peptide (EMPFPK) (pep-04965, v1). PeptideModel. https://peptidemodel.com/card/pep-04965

@peptide{pep04965,
  sequence = {EMPFPK},
  target   = {ace},
  author   = {peptidemodel},
  year     = {2026},
  status   = {computed}
}

related peptides 4 by signal overlap

pep-04726 Blood-pressure-lowering peptide (GPVRGPFP) same target ·5 shared papers

pep-04649 β-casein blood-pressure peptide same target ·5 shared papers

pep-04616 β-casein blood-pressure-lowering peptide same target ·4 shared papers

pep-04979 Blood-pressure-lowering peptide (AVPYPQ) same target ·3 shared papers

references 8 papers

[1]

In silico identification of novel ACE and DPP-IV inhibitory peptides derived from buffalo milk proteins and evaluation of their inhibitory mechanisms

Gu Y; Li X; Qi X; Ma Y; Chan E Amino Acids 2023

doi: 10.1007/s00726-022-03202-z

source scaffold

[2]

Identification of peptides derived from ripened Mihalic cheese and promising properties: in silico and in vitro approaches

Altuntas, S. et al. European Food Research and Technology 2025

doi: 10.1007/s00217-025-04785-z

supporting

[3]

Goat milk-derived bioactive peptides as a health promoter: an insight based on recent in silico studies

Hassan, S. et al. Food Science of Animal Resources 2026

doi: 10.1007/s44463-026-00061-0

supporting

[4]

Milk protein isolate (MPI) as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides

Nongonierma, A. et al. Food Chemistry 2017

doi: 10.1016/j.foodchem.2017.03.123

supporting

[5]

Isolation and Identification of Dipeptidyl Peptidase IV-Inhibitory Peptides from Trypsin/Chymotrypsin-Treated Goat Milk Casein Hydrolysates by 2D-TLC and LC–MS/MS

Zhang, Y. et al. Journal of Agricultural and Food Chemistry 2015

doi: 10.1021/acs.jafc.5b03062

supporting

[6]

Identification of Angiotensin-I-Converting Enzyme Inhibitory Peptides Derived from Sodium Caseinate Hydrolysates Produced byLactobacillus helveticusNCC 2765

Robert, M. et al. Journal of Agricultural and Food Chemistry 2004

doi: 10.1021/jf049510t

supporting

[7]

Casein Fermentate of Lactobacillus animalis DPC6134 Contains a Range of Novel Propeptide Angiotensin-Converting Enzyme Inhibitors

Hayes, M. et al. Applied and Environmental Microbiology 2007

doi: 10.1128/aem.00096-07

supporting

[8]

Milk-derived bioactive peptides

Kashung, P. et al. Food Production, Processing and Nutrition 2025

doi: 10.1186/s43014-024-00280-2

supporting

discussion no comments

sign in to comment